Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for simultaneously determining concentrations of anticoagulant drugs and active metabolite in plasma

A metabolite, plasma technology, applied in the field of plasma drug concentration detection, can solve the problems of low sensitivity and simultaneous detection of dabigatran etexilate without public disclosure, and achieve the effect of high sensitivity

Active Publication Date: 2021-06-25
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Patent CN111812219A provides a method for detecting the concentration of anticoagulant drugs in plasma, which provides a detection method for detecting dabigatran, rivaroxaban and apixaban, but it does not disclose the simultaneous detection of dabigatran etexilate , rivaroxaban, edoxaban, apixaban, and dabigatran
In addition, the lower limit of quantification in this patent is 1ng / mL, and the sensitivity is low

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for simultaneously determining concentrations of anticoagulant drugs and active metabolite in plasma
  • Method for simultaneously determining concentrations of anticoagulant drugs and active metabolite in plasma
  • Method for simultaneously determining concentrations of anticoagulant drugs and active metabolite in plasma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] This embodiment provides the preparation method of reference substance solution, mixed internal standard working solution, standard curve and quality control plasma samples:

[0057] 1. Preparation of reference solution:

[0058] Accurately weigh appropriate amounts of dabigatran etexilate, dabigatran, rivaroxaban, edoxaban, and apixaban reference substances, dissolve them in methanol and constant volume to obtain a concentration of 1 mg·mL -1 Dabigatran etexilate, dabigatran, edoxaban and apixaban stock solutions, and a concentration of 0.75mg·mL -1 The rivaroxaban stock solution, as shown in Table 1, was stored in a -20°C refrigerator. Dabigatran etexilate, dabigatran, rivaroxaban, apixaban and edoxaban stock solution are prepared to contain 5000ng / mL dabigatran etexilate, dabigatran, ritoxaban Reference solution of varoxaban, apixaban and edoxaban.

[0059] Table 1: Stock Solution Preparation

[0060]

[0061]

[0062] 2. Preparation of rivaroxaban-deuteriu...

Embodiment 2

[0075] This example provides the detection of anticoagulant drugs dabigatran etexilate, rivaroxaban, edoxaban, apixaban and active metabolites in pretreated plasma by ultra-high performance liquid chromatography tandem mass spectrometry The method for dabigatran specifically comprises the following steps:

[0076] Step 1. Pretreatment of plasma samples and standard curve plasma samples

[0077] Plasma sample preparation:

[0078] Take 100 μL of plasma sample in a 1.5 mL centrifuge tube, add 890 μL of ice-cold methanol and 1 μg·mL -1 Mix 10 μL of the internal standard solution, vortex and centrifuge (13000g, 4°C, 10min), take the supernatant, blow it to dryness with nitrogen, add 100μL methanol solution containing 1% formic acid to the dry sample and ultrasonically reconstitute, centrifuge (13000g, 4°C, 10 min), take 50 μL of the supernatant, add 450 μL of pure water, mix well, and wait for sample injection analysis.

[0079] Standard curve plasma sample preparation:

[008...

Embodiment 3

[0098] Using the plasma samples provided by the subjects taking anticoagulant drugs, the method in Example 2 was used to analyze the concentration of anticoagulant drugs, and the results were as follows Figure 3.1-3.3As shown in , the determination of the presence of rivaroxaban in one case of plasma samples and the presence of dabigatran etexilate and its metabolite dabigatran in the other case of plasma samples further confirmed the existence of rivaroxaban, dabigatran etexilate and their metabolites The concentration of the product dabigatran was 263.7ng L -1 , 4.4ng·L -1 and 224.0ng·L -1 .

[0099] 【Test verification】

[0100] 1. Linearity

[0101] The weighted linear regression was performed on the concentration (X, ng / mL) of the peak area ratio (Y) of the drug to the internal standard. Among them, the weight coefficient is 1 / X, and the correlation coefficient r of the regression equation is greater than 0.997, as shown in Table 6. The linearity is good and meets th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for simultaneously determining the concentrations of anticoagulant drugs and an active metabolite in plasma. The anticoagulant drugs are dabigatran etexilate, rivaroxaban, edoxaban and apixaban respectively, and the active metabolite is dabigatran. The specificity, precision, accuracy, linearity, stability and the like of the method all meet the analysis requirements of biological samples, the sensitivity is high, and the method can be used for clinical monitoring of therapeutic drugs of dabigatran etexilate, dabigatran, rivaroxaban, edoxaban and apixaban.

Description

technical field [0001] The invention relates to the technical field of plasma drug concentration detection, in particular to a method for simultaneously measuring the concentrations of anticoagulant drugs and active metabolites in plasma. Background technique [0002] Dabigatran (as Figure 1.1 Middle) is a kind of strongly polar amphoteric compound, insoluble in organic solvent, dabigatran etexilate (as Figure 1.2 Middle) is a prodrug, which is converted into dabigatran in vivo to exert anticoagulant effect. Dabigatran etexilate is a new type of synthetic oral anticoagulant inhibitor, which can reversibly competitively inhibit the activity of thrombin and belongs to non-peptide thrombin inhibitors. After oral administration, it is rapidly absorbed through the digestive tract, and is hydrolyzed by esterase in plasma and liver to produce the active metabolite dabigatran, which exerts anticoagulant activity by inhibiting thrombin. Rivaroxaban (as Figure 1.3 in) and apixab...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02G01N30/06G01N30/30G01N30/32G01N30/34G01N30/72
CPCG01N30/02G01N30/06G01N30/30G01N30/32G01N30/34G01N30/72G01N2030/324
Inventor 马春来张雨霏钟明康
Owner AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com